Company intelligence / Profile preview

Hedia

Ownership: Private
Development stage: Commercial

Overview

Hedia has developed and commercialized the Hedia Diabetes Assistant, a CE-marked class IIb medical device that provides personalized insulin dosing recommendations to people with insulin-requiring diabetes. Clinical studies are ongoing to further validate its impact on glycemic control. The next generation of the platform is under development and will soon enter clinical testing[1].

Therapeutic areas: Endocrinology
Modalities: DeviceDigital therapeutic (DTx)
Industry: Digital Health Medical Devices

Partnerships

Glooko Inc. – Integration partnership for advanced bolus insulin dosing solutions combining connected care, remote monitoring, and digital therapeutics[1]

Beyond the preview

Go deeper on Hedia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hedia.

Explore the full profile